TY - JOUR
T1 - Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma
T2 - Final Results of the German OPTIMOB Study
AU - Kriegsmann, Katharina
AU - Bittrich, Max
AU - Sauer, Sandra
AU - Tietze-Stolley, Carola
AU - Movassaghi, Kamran
AU - Grube, Matthias
AU - Vucinic, Vladan
AU - Wehler, Daniela
AU - Burchert, Andreas
AU - Schmidt-Hieber, Martin
AU - Rank, Andreas
AU - Dürk, Heinz A.
AU - Metzner, Bernd
AU - Kimmich, Christoph
AU - Hentrich, Marcus
AU - Kunz, Christian
AU - Hartmann, Frank
AU - Khandanpour, Cyrus
AU - De Wit, Maike
AU - Holtick, Udo
AU - Kiehl, Michael
AU - Stoltefuß, Andrea
AU - Kiani, Alexander
AU - Naumann, Ralph
AU - Scholz, Christian W.
AU - Tischler, Hans Joachim
AU - Görner, Martin
AU - Brand, Franziska
AU - Ehmer, Martin
AU - Kröger, Nicolaus
N1 - Publisher Copyright:
© 2023 S. Karger AG. All rights reserved.
PY - 2023/10/21
Y1 - 2023/10/21
N2 - Introduction: Successful mobilization and collection of peripheral hematopoietic stem cells (HSCs) are necessary for lymphoma patients eligible for myeloablative chemotherapy with subsequent autologous stem cell transplantation (ASCT). Albeit G-CSF alone or combined with chemotherapy is well-established methods for HSC mobilization, up to 40% of the patients fail to mobilize (poor mobilizer, PM). Plerixafor (PLX) is commonly used in PM patients resulting in increased migration of HSCs into peripheral blood and thus improves the collection outcome. Methods: The prospective, multicenter, open-label, non-interventional OPTIMOB study assessed mobilization and collection parameter of patients with lymphoma or multiple myeloma to get deep insights in the treatment of those patients in clinical routine focusing on PM patients. PM was defined as follows: (1) no achievement of ≥20 CD34+ progenitor cells/μL before first apheresis, (2) PLX administration at any time point during the observational period, (3) reduction of the initially planned CD34+ progenitor cell yield as necessity due to failed mobilization or HSC collection, and (4) no performance of apheresis due to low CD34+ progenitor level. Primary objective of the study was to assess mobilization success by the proportion of PM patients achieving >2 × 106 CD34+ progenitor cells/kg body weight on the first day of apheresis. Here, the data of the lymphoma cohort are presented. Results: Out of 238 patients with lymphoma documented in the study, 32% were classified as PM. 87% of them received PLX. Demographic data revealed no obvious differences between PM and good mobilizing (GM) patients. All patients were treated highly individualized prior to mobilization. Majority of all PM patients were able to undergo apheresis (95%) and reached their individual requested CD34+ progenitor cell target (72%). 57% of the PM patients achieved >2.0 × 106 CD34+ progenitor cells/kg body weight on day 1 of apheresis and nearby 70% of them underwent ASCT. Median time to engraftment was similar in PM and GM patients of the lymphoma cohort. Conclusions: Majority of PM patients with lymphoma were successfully mobilized and underwent ASCT. Most of them received PLX during the study.
AB - Introduction: Successful mobilization and collection of peripheral hematopoietic stem cells (HSCs) are necessary for lymphoma patients eligible for myeloablative chemotherapy with subsequent autologous stem cell transplantation (ASCT). Albeit G-CSF alone or combined with chemotherapy is well-established methods for HSC mobilization, up to 40% of the patients fail to mobilize (poor mobilizer, PM). Plerixafor (PLX) is commonly used in PM patients resulting in increased migration of HSCs into peripheral blood and thus improves the collection outcome. Methods: The prospective, multicenter, open-label, non-interventional OPTIMOB study assessed mobilization and collection parameter of patients with lymphoma or multiple myeloma to get deep insights in the treatment of those patients in clinical routine focusing on PM patients. PM was defined as follows: (1) no achievement of ≥20 CD34+ progenitor cells/μL before first apheresis, (2) PLX administration at any time point during the observational period, (3) reduction of the initially planned CD34+ progenitor cell yield as necessity due to failed mobilization or HSC collection, and (4) no performance of apheresis due to low CD34+ progenitor level. Primary objective of the study was to assess mobilization success by the proportion of PM patients achieving >2 × 106 CD34+ progenitor cells/kg body weight on the first day of apheresis. Here, the data of the lymphoma cohort are presented. Results: Out of 238 patients with lymphoma documented in the study, 32% were classified as PM. 87% of them received PLX. Demographic data revealed no obvious differences between PM and good mobilizing (GM) patients. All patients were treated highly individualized prior to mobilization. Majority of all PM patients were able to undergo apheresis (95%) and reached their individual requested CD34+ progenitor cell target (72%). 57% of the PM patients achieved >2.0 × 106 CD34+ progenitor cells/kg body weight on day 1 of apheresis and nearby 70% of them underwent ASCT. Median time to engraftment was similar in PM and GM patients of the lymphoma cohort. Conclusions: Majority of PM patients with lymphoma were successfully mobilized and underwent ASCT. Most of them received PLX during the study.
UR - http://www.scopus.com/inward/record.url?scp=85171804898&partnerID=8YFLogxK
U2 - 10.1159/000531936
DO - 10.1159/000531936
M3 - Journal articles
AN - SCOPUS:85171804898
SN - 1660-3796
VL - 50
SP - 403
EP - 416
JO - Transfusion Medicine and Hemotherapy
JF - Transfusion Medicine and Hemotherapy
IS - 5
ER -
